Article: Aldara[TM] receives FDA approval for treating actinic keratosis.(Brief Article)

3M announced the U.S. Food and Drug Administration was granted marketing approval for Aldara (imiquimod) Cream, 5%, a topical prescription treatment for clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults. Aldara Cream is the first immune response modifier approved for AK.

The FDA's approval of Aldara Cream for AK in early 2004 was based on positive results from two double-blind, randomized, placebo-controlled clinical trials involving 436 patients with multiple AK ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!